What was the problem?
Wounds that are difficult to diagnose place a heavy burden on global healthcare systems. In the UK, it is estimated that around 30% of wounds are not definitively diagnosed, and the burden they place on the NHS is comparable to that of managing obesity. In the USA, the cost is estimated at around $28 billion (almost £22 billion) and between 2.4 and 4.5 million people are affected.
There is no reliable method of determining why some wounds take longer to heal than others. The enzymes that prevent healing cannot be seen, smelt or measured without laboratory equipment.
Mologic set out to develop a rapid point-of-care diagnostic test to identify an imbalance in protease activity. The test would offer device-free operation, using only a simple swab sample and extraction buffer.
Mologic developed a point-of-care test which was able to deliver actionable results in under 15 minutes. Our enzyme activity detection technology was tailored to detect the key neutrophil enzymes MMP’s and HNE, and a swab-based extraction process was developed for optimal sample recovery while meeting clinical best practice.
Clinical trials were conducted to establish threshold performance in accordance with KOL judgement on the wound healing status.
The end product – the world’s first commercially available rapid diagnostic test for chronic wound care – measured protease enzyme activity via a simple, easy-to-read swab sample.
With the help of the test, clinicians could quickly select the best treatment, transforming the time it takes for wounds to heal, promoting patient wellbeing and enabling significant cost savings for the provider.
“The wound diagnostic has helped us, as clinicians, recognise earlier what treatments to provide to our patients. It is also cost effective because it decreases the frequency of patient visits and product use.”
Specialist wound care nurse, UK hospital.